Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Nov 30;14(11):3446-3452.
doi: 10.21037/tau-2025-637. Epub 2025 Nov 25.

From surgery to systemic therapy in von Hippel-Lindau disease: insights from extended follow-up of LITESPARK-004

Lisa M Tachiki  1   2 , Scott S Tykodi  1   2
Affiliations
Editorial

From surgery to systemic therapy in von Hippel-Lindau disease: insights from extended follow-up of LITESPARK-004

Lisa M Tachiki et al. Transl Androl Urol. .
No abstract available

Keywords: Von Hippel-Lindau disease (VHL disease); belzutifan; hypoxia-inducible factor-2α inhibition (HIF-2α inhibition); renal cell carcinoma (RCC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2025-637/coif). L.M.T. reports research funding (institution) from Seagen, Merck, and Erasca; travel support from ASCO Merit Award; advisory board/consultant role from American Journal of Managed Care’s Institute for Value-Based Medicine; and honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from OncLive/MJH Life Sciences and CancerNetwork. S.S.T. reports a consulting role from FirstWord, Bristol-Myers Squibb, AVEO Oncology and Exelixis; honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from OncLive/MJH Life Sciences, Targeted Oncology, CancerNetwork, and Topline Bio; support for attending meetings/travel from DAVA Oncology and KidneyCAN; and research funding (institution) from Xencor, Merck, AVEO Oncology, Bristol-Myers Squibb, Exelixis, Pfizer, Iovance Biotherapeutics and HiberCell. The authors have no other conflicts of interest to declare.

Comment on

References

    1. Shepherd STC, Drake WM, Turajlic S. The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet? Eur J Cancer 2023;182:15-22. 10.1016/j.ejca.2022.12.011 - DOI - PubMed
    1. Bader HL, Hsu T. Systemic VHL gene functions and the VHL disease. FEBS Lett 2012;586:1562-9. 10.1016/j.febslet.2012.04.032 - DOI - PMC - PubMed
    1. Cicchetti R, Basconi M, Litterio G, et al. Advances in Molecular Mechanisms of Kidney Disease: Integrating Renal Tumorigenesis of Hereditary Cancer Syndrome. Int J Mol Sci 2024;25:9060. 10.3390/ijms25169060 - DOI - PMC - PubMed
    1. Kim E, Zschiedrich S. Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies. Front Pediatr 2018;6:16. 10.3389/fped.2018.00016 - DOI - PMC - PubMed
    1. Kwon T, Jeong IG, Pak S, et al. Renal tumor size is an independent prognostic factor for overall survival in von Hippel-Lindau disease. J Cancer Res Clin Oncol 2014;140:1171-7. 10.1007/s00432-014-1654-y - DOI - PMC - PubMed